Group 1 - The core point of the announcement is the successful completion of performance commitments by Xiamen Luyi Color Masterbatch Co., Ltd., which exceeded the cumulative net profit commitment of 78 million yuan for 2023 and 2024, achieving a total net profit of 78.82 million yuan [1][2] - The Supervisory Board meeting was held on May 21, 2025, with all three supervisors present, and the meeting complied with relevant laws and regulations [1] - The performance commitment report was audited by Lixin Certified Public Accountants, confirming that there were no impairment signs for the assets of Xiamen Luyi Color Masterbatch Co., Ltd. as of December 31, 2024 [2] Group 2 - The Supervisory Board approved the implementation of excess performance rewards and related transactions, deeming them reasonable and not harmful to the interests of the company and its shareholders [2] - The voting results for the proposals were unanimous, with all three votes in favor and no opposition or abstentions [2]

Group 1: Company Overview and Business Segments - The company operates in four main business segments: power distribution equipment, electric vehicle charging stations, photovoltaic and wind power EPC, and biomedicine [2][3][11] - The acquisition of 51% of Rui'en Pharmaceutical is a strategic move to enhance the company's presence in the biomedicine sector [11][12] Group 2: Financial Performance and Goals - In Q1 2025, the company reported a revenue of 60.76 million CNY, a year-on-year increase of 94.47% due to the consolidation of Rui'en Pharmaceutical [11][12] - The company aims to improve its overall financial performance and mitigate delisting risks by enhancing operational management and cost control [3][4][12] Group 3: Risk Management and Compliance - The company is under delisting risk warning due to negative net profit and low revenue, with efforts being made to resolve these issues [4][6][12] - The company plans to apply for the removal of risk warnings once it meets the necessary criteria set by the Shenzhen Stock Exchange [4][6] Group 4: Strategic Initiatives and Future Plans - The company intends to expand its market presence both domestically and internationally, focusing on partnerships and order fulfillment [4][11] - Emphasis will be placed on technological advancements and maintaining customer relationships to enhance operational efficiency and brand reputation [4][11] Group 5: Shareholder Engagement and Market Confidence - The company reassures shareholders that there are no current plans for major asset disposals or reductions in shareholding by major stakeholders [13] - Continuous efforts are being made to improve shareholder value and market confidence through strategic management and operational improvements [13]

Group 1 - The company will hold a shareholders' meeting on May 23, 2024, at 10:00 AM in Beijing, with attendance required from all registered shareholders and representatives [6][9] - The meeting will follow specific rules to ensure order and efficiency, including a combination of on-site and online voting [4][5] - The agenda includes the presentation of various reports and proposals for shareholder approval, including the annual financial report and profit distribution plan [10][11][12] Group 2 - The company reported a net loss of approximately 72.87 million yuan for the year 2024, with retained earnings at -525.30 million yuan, leading to a proposal of no profit distribution for the year [13][16] - The company plans to address its significant losses, which exceed one-third of its paid-in capital, by optimizing cost structures and exploring strategic transformations [16][18] - The company has proposed to purchase directors and officers liability insurance to enhance risk management and protect the interests of investors [19][20] Group 3 - Three independent directors have resigned due to personal reasons, prompting the need for a replacement election at the upcoming shareholders' meeting [21][22] - The board has recommended three candidates for the independent director positions, ensuring compliance with legal requirements [22][23] - The company acknowledges the contributions of the departing independent directors and expresses gratitude for their service [22]

Financial Performance - The company achieved a net profit attributable to shareholders of 61.77 million yuan in 2024, representing an increase of 85.24% compared to the previous year [2] Dividend Distribution - In 2024, the company conducted two cash dividend distributions: 1. In July 2024, a cash dividend of 0.2 yuan per 10 shares was distributed, totaling 11,704,328.44 yuan (including tax) [3] 2. In December 2024, a cash dividend of 0.33 yuan per 10 shares was proposed, totaling 19,312,141.93 yuan (including tax) [3] Business Performance - The gross margin for the specialized chemical business dropped to 1% due to high volatility in silver prices, which constitute a significant portion of product costs [4] - The company is actively participating in the photovoltaic industry to expand market share, even with low margins, to establish a competitive advantage [4] Future Outlook - The performance compensation expected to be paid in 2025 may impact the company's consolidated financial results, with the final amount to be determined through negotiations with relevant parties [4]

《每日经济新闻》记者注意到，世纪华通的股价从去年7月开始波动上涨，从约3元/股（前复权）上涨至目 前约8元/股。 去年，中国证监会对世纪华通作出行政处罚，认定公司2018年至2022年年报商誉有关情况存在虚假记载， 同时还存在虚构业务或提前确认收入的情况，最新的警示函则是这一处罚的延续。 此外，世纪华通对相关财务数据进行了会计差错更正，致使子公司原本已"完成"的业绩承诺未能达成，相 关业绩承诺人需承担超过1亿股的业绩补偿责任。 七名高管遭警示 每经记者｜赵李南 每经编辑｜魏官红 5月12日，ST华通（SZ002602，股价8.01元，市值596.95亿元，即"世纪华通"）公告称，公司相关人员收到 浙江证监局下发的警示函。 此前称完成业绩承诺，现需补偿12.6亿元 2019年，世纪华通向盛趣科技包括曜瞿如、熠趣盛及吉虞梵在内的29名股东以发行股份及支付现金的方式 购买其合计持有的上海盛趣科技（集团）有限公司（原名盛跃网络科技（上海）有限公司，简称"盛趣科 技"）100%股权。 补偿义务人承诺，盛趣科技在业绩承诺期（即2018年度、2019年度和2020年度）内实际实现的合并报表扣 除非经常性损益后归属于母公司股 ...

Core Viewpoint - Tongrun Equipment has received a cash compensation of approximately 45 million yuan from Chint Electric and other parties due to unmet performance commitments related to the acquisition of Wenzhou Antai Power System Co., Ltd. two years ago [1][2]. Group 1: Acquisition and Compensation Details - The cash compensation is a result of Antai Power failing to meet its performance commitments during the agreed period [2][3]. - Chint Electric, which became the controlling shareholder of Tongrun Equipment through the acquisition, is involved in this compensation process, indicating a clear financial accountability between the parent and subsidiary companies [2]. - The acquisition involved Chint Electric transferring 86.97% of Antai Power's shares to Tongrun Equipment for approximately 730 million yuan, which subsequently led to Tongrun becoming a subsidiary of Chint Electric [2]. Group 2: Performance Commitments and Financial Impact - Chint Electric had committed that Antai Power would achieve net profits of no less than approximately 90 million yuan, 110 million yuan, and 140 million yuan for the years 2023, 2024, and 2025, respectively [2]. - As of the end of the performance commitment period, Antai Power achieved a cumulative performance of approximately 180 million yuan, resulting in a completion rate of 91.06% [4]. - The reasons for not meeting the performance commitments included fluctuations in revenue recognition due to project-based income and a decline in storage product prices, which affected Antai Power's revenue in 2024 [4].

（原标题：康芝药业年报亏损，控股股东约6亿元业绩补偿承诺何时兑现？） 2025年4月29日，康芝药业股份有限公司（300086.SZ，下称"康芝药业"）发布2024年年报及2025年第一 季度报告。报告显示，2024年度及2025年第一季度，该公司实现的归母净利润分别为-2.16亿 元、-969.17万元，接连出现亏损。 同一天，康芝药业还披露了其控股股东海南宏氏投资有限公司（下称"宏氏投资"）因未按照约定履行业 绩补偿承诺，被中国证券监督管理委员会海南监管局（下称"海南证监局"）采取了责令改正的行政监管 措施。 业绩亏损 高管涨薪 自称为国内领先儿童大健康企业的康芝药业，近年来业绩大起大落，在最近的六年中，有三年出现亏 损；从2021年起，更是出现了盈亏交替的趋势。2021年，康芝药业实现归母净利润0.11亿元，2022年亏 损1.88亿元，2023年盈利0.12亿元，2024年再度由盈转亏。 具体来看，2024年康芝药业实现营业收入4.73亿元，同比下降36.07%；实现归母净利润-2.16亿元，同比 下降1975.20%；实现扣非归母净利润-2.13亿元，同比下降1671.71%。 对于业绩大幅下滑的原 ...

具体详见公司于2020年4月28日在《证券时报》、《上海证券报》及巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于百卓网络2019年度业绩承诺实现情况及业绩补偿方案的公 告》（公告编号：2020-028）。 为维护公司及全体股东的利益，公司依据协议及法律法规规定，向苏州仲裁委员会提起对被申请人（陈 海滨、崔泽鹏、宋禹、陈裕珍、刘美学以及南海金控）的仲裁，请求苏州仲裁委员会裁决被申请人向公 司进行业绩补偿，支付违约金并承担本案的全部仲裁、保全费。 具体详见公司于2020年7月28日在《证券时报》、《上海证券报》及巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于业绩补偿事项提起仲裁的公告》（公告编号：2020-063）。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002491 证券简称：通鼎互联 公告编号：2025-013 通鼎互联信息股份有限公司关于业绩补偿事项进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、业绩承诺补偿及仲裁情况 2016年6月7日，公司因收购北京百卓网络 ...

星标 ★ IPO日报 精彩文章第一时间推送 近期，嘉必优生物技术（武汉）股份有限公司（下称"嘉必优"）公告称，拟以发行股份及支付现金的方式向王树伟、董栋等13名交易对方购买欧易 生物63.2134%的股权，并募集配套资金，交易价格8.31亿元。 嘉必优在2024年营收和净利润双增长，但其在2021年—2023年净利润波动剧烈。2023年净利润虽有所回升，但风险仍存。此次，公司以8.31亿元的溢价收 购欧易生物，未来业绩兑现存不确定性，机遇与挑战并存。 制图：佘诗婕 01 净利润不稳定 嘉必优成立于2004年，2019年12月在科创板上市。公司是国内较早从事微生物合成法生产多不饱和脂肪酸及脂溶性营养素的企业之一。主要产品为多不饱 和脂肪酸ARA（花生四烯酸）、藻油DHA（二十二碳六烯酸）等。这些产品广泛应用于婴幼儿配方食品、膳食营养补充剂、健康食品、特殊医学用途配 方食品以及动物营养、个护美妆等领域。客户方面，其与雀巢、达能、嘉吉、飞鹤、伊利、君乐宝等国内外知名企业建立了长期的合作关系。 2024年，嘉必优实现了营收和净利润的双增长。其营收为5.55亿元，同比增长25.06%；归母净利润为1.24亿元，同比增长 ...

中准会计师事务所（特殊普通合伙） Zhongzhun Certified Public Accountants 关于对吉药控股集团股份有限公司的关注函的回复 深圳证券交易所创业板公司管理部： 根据贵部下发的关于对吉药控股集团股份有限公司（以下简称"吉药控股" 或"公司"）的关注函（创业板关注函〔2023〕第 39 号）的要求，中准会计师 事务所（特殊普通合伙）（以下简称"本所"）组织相关人员，对贵部关注函中 提及的问题，严格按照要求进行认真、详细的核查，就相关事项回复如下： 问题 2：业绩预告显示，公司收到业绩补偿款、大股东豁免公司债务、子公 司少数股权被司法拍卖等事项预计将累计增加公司净资产 94,559.21 万元；上 述事项未经过会计师事务所审计，能否增厚 2022 年末净资产尚存在重大不确定 性。 请你公司结合上述事项的筹划、决策及执行过程、商业合理性、程序合法合 规性以及是否存在应披露未披露的"抽屉协议"或其他交易安排等，充分说明相 关事项会计处理的确认依据及其合理性，并明确说明公司是否可能因此承担其 他或有债务、上述事项是否存在前提条件或后续安排、上述事项是否与公司正在 筹划的重大事项（如有）为一 ...